Accretion Nutraveda Limited (BOM:544694)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Manufacturing and Sale of Pharmaceutical Products	160.49M	50.69M	30.03M	5.85M
Manufacturing and Sale of Pharmaceutical Products Growth	216.62%	68.81%	413.23%	-
Total	160.49M	50.69M	30.03M	5.85M
Total Growth	216.62%	68.81%	413.23%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India	154.62M	49.12M	28.85M	5.85M
India Growth	214.79%	70.24%	393.16%	-
Export	5.40M	934.00K	178.00K	-
Export Growth	478.27%	424.72%	-	-
Total	160.02M	50.05M	29.03M	5.85M
Total Growth	219.70%	72.41%	396.21%	-

Source: S&P Global Market Intelligence.